Recombinant human interleukin-4 (IL-4) will be administered to patients with non-small cell lung (NSCL) cancer in order to determine the anti-tumor activity of IL-4 and the duration of response and to evaluate safety and toxicity of IL-4 when given subcutaneously three times weekly for six months.
Showing the most recent 10 out of 470 publications